GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.
about
Nonhuman primate models for HIV/AIDS vaccine developmentSynthetic DNA vaccine strategies against persistent viral infectionsPrevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccineGM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primatesPreclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.Vaccine design for CD8 T lymphocyte responsesVaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.Use of nonhuman primate models to develop mucosal AIDS vaccines.Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routesEnv-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virusDifferences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapySoluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques.DNA/MVA Vaccines for HIV/AIDSEnhancing SIV-specific immunity in vivo by PD-1 blockade.Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulationsPhase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus.Clinical applications of DNA vaccines: current progress.What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.Technologies for enhanced efficacy of DNA vaccines.Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs.HIV DNA Vaccine: Stepwise Improvements Make a Difference.HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccineSoluble mediators of inflammation in HIV and their implications for therapeutics and vaccine developmentThe catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responsesStrong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus VaccineCo-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 virusesPotent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing.Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.Non-neutralizing antibodies in prevention of HIV infection.Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.The Impact of Poxvirus Vector Priming, Protein Co-Administration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
P2860
Q26861148-F0782470-5418-4307-8ADA-5821517D69BAQ27016078-F8D060CE-47E7-4C93-B855-C6CCCF7D373AQ28742137-530A051A-BE75-4B2D-BE66-848D06545C3AQ28751705-A91AA0B6-7F4D-4C71-AB52-CE50D467905CQ30374995-EB756B40-E6F9-4BC2-9798-3059D6997BC4Q30411492-A323635E-EE6B-4B5A-A5FB-726E8E767B90Q33575384-281998E9-4180-4801-A996-2D59FA5673C2Q33666002-838D7528-1D1F-4F31-BE35-A2D8EAAFCE94Q33743758-5C325017-6026-4DD6-8FF0-4C5B6552121BQ33769283-08A13F9F-2103-4A22-B460-56194CF8299AQ33865785-AD8350CD-8C7F-4E21-9147-04E08E6D7496Q34096530-A7D274F1-168E-40B7-A95C-EEB32500BCCAQ34245386-66EA76C6-B27E-499D-A61A-E47A46C4CEC1Q34492802-E51A8629-2A79-49B0-AB0D-E5085D52F20CQ34601856-618B2FC2-1037-4C01-9797-CE7CEB2A0716Q34641666-CB12A275-2681-4898-A64C-ACF9D35B9921Q34772727-983E8504-FBA7-4A49-A9D5-D54C92C6E086Q35232804-2D148A43-B0D8-4121-9375-C214294659C3Q35452312-03D74374-50BB-443F-8D7D-D19A9C70EC2FQ35641144-6DA58FAB-144C-42CF-B4D1-4396AB0F11C5Q35754196-7916C563-0099-416A-89AB-11C1E6D12AFEQ35802958-BE9948DD-F1E9-46C5-AA34-03C33C05E1DAQ35824686-02410A97-D0E4-4E95-B897-856BD6E35BA6Q35826742-22E8CFD0-949B-4250-87A0-20BADA84B689Q35883997-D4EFD0D5-5B19-4D55-9796-C10398727F80Q36007614-0A6B5F4C-BEA0-4639-B4B7-B5C0F7070D36Q36141586-C4F91F4E-8530-496C-A603-D27FA40CAE2DQ36162133-8FC85C81-0B3A-466E-A940-6A1CE668C503Q36256348-3FBFB5D9-E7AC-4CC0-B628-DC50CC27EE7EQ36708266-B4B2C549-364E-4E51-8E8F-52B1C338C247Q37018558-8A1DB9C3-BEA3-4A52-9C01-4BEA2CD540EBQ37087055-EB6D2DE7-4F5C-4DBC-B3AF-930FE22E8FC6Q37253001-17468680-C2AE-4DB6-9CF4-B5E5627C16C5Q37522856-175A3F68-FC28-4865-9E45-2F000848BA09Q38058120-AB81C205-6FE1-4953-83CC-B652B14E9455Q38356290-3F172ADF-1E1B-4067-AA53-61F25895D6BAQ38618790-014E3EFC-4644-45C8-8EB1-6C6691EF50ECQ38621582-3A0E3D26-D3BD-46A8-A03B-D4BACAB202BEQ40071705-B9AF3469-84CD-4955-AB34-709386E40D51Q40077472-9D71AF81-4F0B-4224-A4D8-2ADBFDE66E4A
P2860
GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
GM-CSF DNA: an adjuvant for hi ...... mmunodeficiency virus vaccine.
@ast
GM-CSF DNA: an adjuvant for hi ...... mmunodeficiency virus vaccine.
@en
type
label
GM-CSF DNA: an adjuvant for hi ...... mmunodeficiency virus vaccine.
@ast
GM-CSF DNA: an adjuvant for hi ...... mmunodeficiency virus vaccine.
@en
prefLabel
GM-CSF DNA: an adjuvant for hi ...... mmunodeficiency virus vaccine.
@ast
GM-CSF DNA: an adjuvant for hi ...... mmunodeficiency virus vaccine.
@en
P2093
P2860
P1433
P1476
GM-CSF DNA: an adjuvant for hi ...... mmunodeficiency virus vaccine.
@en
P2093
Dalma Vödrös
Francois Villinger
Harriet L Robinson
Lakshmi Chennareddi
Lazarus Ofielu
Linda S Wyatt
Pamela A Kozlowski
Rama Rao Amara
Robert L Wilson
P2860
P304
P356
10.1016/J.VIROL.2007.07.017
P407
P577
2007-08-14T00:00:00Z